Tommy John, a 31-year-old pitcher for the Los Angeles Dodgers, felt a pop in his left arm during a July game. The ulnar collateral ligament in his elbow was gone. Standard medicine offered no return to the mound. On September 25, 1974, Dr. Frank Jobe performed an unprecedented procedure at Centinela Hospital Medical Center. He removed a palmaris longus tendon from John’s right forearm, drilled holes in the humerus and ulna bones of the left elbow, and wove the tendon through them to create a new, artificial ligament. Jobe gave the surgery a fifty-fifty chance of success.
Its significance was not immediate. John missed the entire 1975 season. He returned in 1976 and pitched for fourteen more years, winning 164 games after the operation. The surgery, now universally called Tommy John surgery, demonstrated that a devastating throwing injury was not a career terminus. It recalibrated the economic and physical lifespan of pitchers. Teams became more willing to invest in young arms, knowing a catastrophic tear was now reparable.
A common misunderstanding is that the surgery enhances performance beyond original capacity. The data does not support this. A 2013 study in *The American Journal of Sports Medicine* found major league pitchers returned to their pre-surgery levels of performance, not beyond them. The surgery restores, it does not upgrade.
The lasting impact is a statistical reality in modern baseball. Over a quarter of current Major League pitchers have undergone the procedure. It transformed orthopedic sports medicine, providing a blueprint for soft-tissue replacement that extended to other joints. Jobe and John shifted the paradigm from accepting catastrophic injury to engineering a solution. The surgery saved careers, altered front-office strategy, and made the torn UCL a rite of passage rather than a retirement notice.